IMMUNODIAGNOSTICS  |  IMMUNOMONITORINGImmuQuad Biotech   ·   Contact@ImmuQuad.com

Peer-reviewed clinical evidence

Published research has evaluated Seq-MRD technology in pediatric B-ALL and in patients monitored after CAR-T cell therapy.

Overview of the pediatric B-ALL Nature Communications study
Nature Communications · 2023

NGS-MRD across immunoglobulin rearrangements in pediatric B-ALL

Chen and colleagues evaluated IGH, IGK and IGL rearrangement-based MRD in a single-center pediatric B-ALL cohort. The study used Seq-MRD technology developed by ImmuQuad Biotech.

430Pediatric B-ALL patients enrolled
399Patients with at least one trackable Ig clone
92.8%Trackable-clone rate in the cohort
5.5%Additional patients trackable through IGK/IGL without IGH
  • Patients with NGS-MRD <0.01% at end of induction or <0.0001% at end of consolidation had 3-year event-free survival above 95% in this cohort.
  • IGH-MRD was prognostic at end of induction and end of consolidation.
  • At end of induction, NGS identified a higher-risk group among patients with flow-cytometry MRD below 0.01%.
Read the paper
Bone Marrow Transplantation · 2022

NGS-MRD after CAR-T cell therapy

Huang and colleagues retrospectively evaluated post-CAR-T NGS-MRD and flow-cytometry MRD in 20 patients with relapsed/refractory B-ALL who achieved complete remission.

20Patients with relapsed/refractory B-ALL
63Samples evaluated
73%NGS/flow concordance at a 0.01% threshold
Day 30Post-CAR-T NGS-MRD evaluated for prognostic value

The study reported discordant NGS and flow results in 17 of 63 samples and evaluated the prognostic value of day-30 NGS-MRD after CAR-T therapy.

Read the paper
Intellectual property & recognition

Developed by ImmuQuad

ImmuQuad reports that Seq-MRD has received three Chinese invention patents and three software copyright registrations. The company also reports European CE registration for a human B-lymphocyte MRD gene detection kit.

  • CN 106957906 B — primer combination and kit for high-throughput MRD detection in T-cell leukemia.
  • CN 109652518 B — MRD detection kit.
  • CN 109680062 B — MRD detection method.

Regulatory status and available configurations should be confirmed with ImmuQuad for the intended market and use.

Selected publications

Discuss a Seq-MRD project with ImmuQuad

Clinical testing, translational research, clinical trials and biopharma collaborations.

Contact our team